Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus helveticus CM4
- Development stage
- Preclinical
- Lead developer
- Asahi Group Holdings
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus helveticus CM4 is a specific strain of probiotic bacteria utilized in fermented milk products for its health-promoting benefits. The active component is the live L. helveticus CM4 microorganism itself. This strain is distinguished by its highly efficient proteolytic system, which includes enzymes like PrtY proteinase. During milk fermentation, these enzymes break down milk proteins to produce bioactive peptides, notably Val-Pro-Pro (VPP) and Ile-Pro-Pro (IPP). These peptides function as inhibitors of the angiotensin-I-converting enzyme (ACE), a key regulator of blood pressure. [7] Clinical studies have indicated that products containing L. helveticus CM4 can lower blood pressure in individuals with high-normal blood pressure or mild hypertension. [11] Additional reported health benefits include the amelioration of dermatitis symptoms and the improvement of sleep quality in elderly populations.
- Other names
- L. helveticus CM4
02
Targets
ACE (Angiotensin Converting Enzyme)
Beyond the preview
Go deeper on Lactobacillus helveticus CM4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus helveticus CM4.